Vectura Share Discussion Threads

[soundbuy] 24/4/2017 10:16

One wonders if recent weakness was Singers' clients duly departing.......

[pooroldboy55] 24/4/2017 10:11

my when this goes it goes!!!!!!!!!!!!!!!!!

[diesel] 24/4/2017 10:05

You can see why shorting is so effective, so much easier to get a negative effect than a positive one! How long have we seen all the broker targets north of 200 yet one broker downgrades and whoosh...not even sure that the success of 315 is factored in at these levels.

[alexchry] 24/4/2017 09:35

Soundbuy-depends what happens on May 10th as to whether it was a brave call or a prudent one. The market seems to be betting on prudence, VEC were over 160p when Mylan got the knock back so even without the Singer sell note the share price has been weak.

[soundbuy] 24/4/2017 09:31

'Following a review of product-level forecasts, we have reduced FY2017-18e revenue forecasts by 6.6% & 10.9% respectively. Following Mylan’s generic Advair® setback, we have also downgraded the likelihood of success for VR315 in the US. Although we remain impressed by the depth of Vectura’s pipeline, the potential valuation upside does not currently outweigh the risk of VR315 non-approval or delayed approval. We downgrade to Sell ahead of the 10th May GDUFA date with a TP of 131p (from 202p). '

[soundbuy] 24/4/2017 09:27

Prudent? Perhaps....

Rather a brave call on their part....

[alexchry] 24/4/2017 09:15

When the Mylan advair generic got a knock back, it was only to be expected that there would be a shadow of over Vectura's generic. At the moment we don't know whether the issue concerning Mylan's generic is specific to them or has raised the bar for everyone. It's possible there has been a leakage of information but it may just be that Singer are taking a prudent view and hence the sell recommendation. I'm hanging on until May 10th, I might live to regret it but I'm hoping that at last we'll have some good news.

[soundbuy] 24/4/2017 08:52

No access to note but picked up that they downgrade FY2017-18e & downgraded likely US success of VR315 following Mylans generic setback


From a twitter feed so none too sure of validity..........

[carpadium] 24/4/2017 08:38

So why the strong sell signal from this broker, their target 202 in Jan to 131 now?
What's changed in their view?

Does the GDUFA goal date refer to ON the day or BY that date. Any leakage could maybe explain.

[soundbuy] 24/4/2017 08:13

Vectura Group PLC VEC N+1 Singer Sell 156.30 148.30 202.00 131.00 Downgrades

[popper joe] 19/4/2017 15:49

Correction ! In the past ten days.

[a1ord53] 19/4/2017 15:45

So higher estimated target prices from analysts so low actual share price
Short sellers enjoying free ride imo.

[popper joe] 19/4/2017 15:45

Pound has risen against the dollar by about 3.5% this week, which is slightly less than the fall that VEC has seen.

[pooroldboy55] 19/4/2017 15:08

Just think its Balls needed !!!!!!!!!!!

[soundbuy] 19/4/2017 14:48

Positions being taken ahead of the 10th? The market? Crystal balls required........

[fhmktg] 13/4/2017 18:14

Double or even a treble bottom formed?Roll on May 10th!Happy Easter break folk!

[alexchry] 12/4/2017 15:19

Have to agree, I think the share price is sitting on the fence and will move significantly one way or the other on May 10th. Numis comments are positive but Mylan have kept quiet about their refusal so we don't know whether it's something specific to their generic or whether the FDA have raised the bar for all generics. I'm just holding on and hoping.

[carpadium] 12/4/2017 15:11

Everything to play for .. see VEC going to 170-180 in pretty short order upon approval or back to 135-140 on disappointment. Failure most certainly not currently priced in.

[dontay] 12/4/2017 14:30

An Interesting update from Barclays on how Numis view the Hickma/Vectura generic.It said that following Mylan's Complete Response Letter, the market is now overly discounting Hikma's prospects for gaining approval of its generic version of GlaxoSmithKline's bestselling asthma drug Advair this year.Numis reckons Hikma has a stronger chance of approval than Mylan because it included 12-18 year olds in its study and has benefited from the expertise of Vectura, a business that, unlike Mylan, has a generic version of Advair Diskus approved in Europe in partnership with Sandoz."In our opinion the current (Hickma) share price is well underpinned by the core business (more than 25% upside), with a free option on generic Advair. This is an asymmetric risk worth taking, with the catalyst now a month away and potential for more than 50% returns if Hikma's generic Advair is approved first time, or with minor deficiencies."In its final results on 15 March, Hikma said it expected revenue for the Generics business to be around $800m this year, with an improvement in the mix of sales and new product launches more than offsetting the impact of increased competition on the marketed portfolio and a reduction in contract manufacturing revenue.The group said certain new launches were expected to contribute around 15% of Generics revenue in 2017, primarily generic Advair, which was assumed to be launched in the second half of the year.

[carpadium] 05/4/2017 18:57

Dontay...the EUR5m is very welcome but it's the vote of confidence that's key, isn't it.
Ablynx are addressing RSV infection with the Fox device and making good progress.
Future parties considering FOX delivery for their products may well think 'if it's good enough for Bayer' ...... :~>

[dontay] 05/4/2017 18:24

Carpadium... yes, only little acorn, but could turn into a nice little earner over time so all to the good.

[carpadium] 05/4/2017 14:02

Another welcomed announcement.

[alexchry] 04/4/2017 16:32

Had to sell a few thousand today, got 154 but kicking myself for not selling a couple of weeks ago. However, I'd have been delighted at the thought of selling at 154 two months ago so I'm not too unhappy.

[sarahbudd] 04/4/2017 12:58

its tomorrow 5th